A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
This research study is testing a new medicine called LY4584180. It's for adults who have specific types of blood cancer, such as Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, or follicular lymphoma, and who have already received other treatments for their cancer. The main goals are to understand if the new medicine is safe, how effective it is in treating these cancers, and how the body processes the medication. Researchers will also look at how much of the medicine gets into the bloodstream and how long it takes for the body to get rid of it. If you join, your involvement in the study could last for about 9 months, or possibly longer, including the initial checks.
At a glance
What is this study about?
This study is focused on improving treatments for certain blood cancers, specifically types of lymphoma, in adults. These cancers include Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. We understand that finding effective treatments is very important, and this research aims to investigate a new medication called LY4584180.
The main purpose of this study is to carefully look at how safe this new medicine is for patients. We also want to understand how well it works against the cancer. Another important part of the study is to learn about how the body handles the medicine – how much of it gets into the bloodstream and how quickly the body removes it. This information helps doctors understand the best way to use new medicines.
Participants in this study would be adults who have previously received treatment for their blood cancer. The hope is that this new medicine could offer another treatment option for these specific cancers. This is what we call a 'Phase 1' study, which means it's one of the first steps in testing a new medicine in people to make sure it's safe and to help us understand the right dose.
Key takeaways
- This study is for adults with specific types of blood cancer who have run out of standard treatment options.
- It tests a new medicine called LY4584180, along with Rituximab, to see if it's safe and helps treat the cancer.
- Participation could last around 9 months or more, involving regular clinic visits.
- You would be helping to find new treatment options for blood cancers.
- You can stop participating at any time without affecting your medical care.
Who may be eligible?
To join this study, you must be an adult, 18 years or older, and have certain types of blood cancer like diffuse large B-cell lymphoma, follicular lymphoma, or other types of Non-Hodgkin lymphoma. You should have already tried at least two other types of treatment for your cancer, or not be able to have the usual available treatments. It's also important that your cancer can be measured, and you should have recovered from any immediate side effects of your previous cancer treatments.
There are also some reasons why you might not be able to join. For example, if you have another active cancer, or if your lymphoma has spread to your brain or spinal cord (unless it was previously treated and is now stable and approved by the study doctor). You also can't join if you have certain infections like Cytomegalovirus, hepatitis B or C, or uncontrolled HIV. Significant heart problems would also mean you can't take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, or follicular lymphoma?
- Have you already had at least two previous treatments for your cancer, or are other treatments not suitable for you?
- Do you have a measurable tumour that can be tracked?
- Have you generally recovered from the immediate effects of your last cancer treatment?
- Do you not have an active second cancer, serious heart problems, or certain active infections (like uncontrolled HIV or hepatitis)?
What does participation involve?
If you decide to join this study, your involvement would involve several stages. First, there's a screening period to make sure you meet all the requirements. If you do, you'll start receiving the study medicine, LY4584180. You will also receive another medicine called Rituximab. This will involve regular visits to the clinic for treatments, check-ups, and tests like blood samples to see how you're responding and how you're tolerating the medicine. These visits help the study team monitor your health and the effects of the treatment.
The study team will explain exactly what each visit will involve, how often you'll need to come in, and what kinds of tests you'll have. For each participant, the total time of being in the study, including all the initial checks and follow-up appointments, could be around 9 months, or potentially longer depending on your individual situation and response to the treatment.
Potential risks and benefits
Locations (46)
- Mayo Clinic - ScottsdaleVerified postcodeScottsdale, United States· Not yet recruiting
- City of HopeVerified postcodeDuarte, United States· Recruiting
- University of California, Los Angeles (UCLA) - Medical CenterVerified postcodeLos Angeles, United States· Not yet recruiting
- University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer CenterVerified postcodeSan Francisco, United States· Not yet recruiting
- Colorado Blood Cancer InstituteVerified postcodeDenver, United States· Recruiting
- University of Miami - Sylvester Cancer CenterVerified postcodeMiami, United States· Not yet recruiting
- Florida Cancer Specialists - SarasotaVerified postcodeSarasota, United States· Recruiting
- Emory University HospitalVerified postcodeAtlanta, United States· Recruiting
- Massachusetts General HospitalVerified postcodeBoston, United States· Recruiting
- Dana-Farber Cancer InstituteVerified postcodeBoston, United States· Recruiting
- Mayo Clinic - RochesterVerified postcodeRochester, United States· Not yet recruiting
- Columbia UniversityVerified postcodeNew York, United States· Recruiting
Common questions
What kind of cancers is this study for?
This study is for adults with certain types of blood cancer, including Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma, who have had previous treatments.
What is LY4584180?
LY4584180 is a new medicine being tested in this study. We are researching its safety and how well it works for these blood cancers.
How long will I be in the study?
The study could last about 9 months or possibly longer, depending on your individual situation and how you respond to treatment.
Will I still receive other treatments?
In this study, you would receive the new medicine LY4584180 along with Rituximab. The study team will explain how this fits with your previous treatments.
What is a Phase 1 study?
A Phase 1 study is usually the first time a new medicine is tested in people. The main goals are to make sure it's safe and to find the right dose.
How to find out more
Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.